Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2010 2
2011 1
2013 2
2014 2
2015 6
2016 2
2017 1
2019 2
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Clinician Perspectives on Using Pharmacogenomics in Clinical Practice.
Unertl KM, Jaffa H, Field JR, Price L, Peterson JF. Unertl KM, et al. Per Med. 2015;12(4):339-347. doi: 10.2217/pme.15.10. Per Med. 2015. PMID: 26635887 Free PMC article.
AIM: To describe the knowledge and attitudes of clinicians participating in a large pharmacogenomics implementation program. ...CONCLUSIONS: Clinicians identified their own knowledge deficits, workflow integration, and longitudinal responsibility as challenge …
AIM: To describe the knowledge and attitudes of clinicians participating in a large pharmacogenomics implementation program. . …
Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian.
Wu AH, Babic N, Yeo KJ. Wu AH, et al. Per Med. 2009 May;6(3):315-327. doi: 10.2217/pme.09.1. Per Med. 2009. PMID: 29783510
Despite widespread interest in personalized medicine, the implementation of clinical pharmacogenomics has been slow. The major issue for clinicians is the lack of evidence that pharmacogenomic testing improves clinical outcomes and that testing …
Despite widespread interest in personalized medicine, the implementation of clinical pharmacogenomics has been slow. The major …
Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality.
St Sauver JL, Bielinski SJ, Olson JE, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Caraballo PJ, Takahashi PY, Roger VL, Rohrer Vitek CR. St Sauver JL, et al. Am J Med. 2016 Oct;129(10):1093-1099.e1. doi: 10.1016/j.amjmed.2016.04.009. Epub 2016 May 5. Am J Med. 2016. PMID: 27155109 Free PMC article.
BACKGROUND: Limited information is available regarding primary care clinicians' response to pharmacogenomic clinical decision support (PGx-CDS) alerts integrated in the electronic health record. METHODS: In February 2015, 159 clinicians in the Mayo Cli …
BACKGROUND: Limited information is available regarding primary care clinicians' response to pharmacogenomic clinical de …
Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.
Pushpam D, Bakhshi S. Pushpam D, et al. Daru. 2020 Jun;28(1):371-385. doi: 10.1007/s40199-019-00321-z. Epub 2020 Jan 3. Daru. 2020. PMID: 31900888 Free article. Review.
OBJECTIVE: In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, bosutinib, ponatinib and radotinib with focus on pharmacogenomic studies with clinical end points. We have discussed the key p …
OBJECTIVE: In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, …
Perspectives on genetic and genomic technologies in an academic medical center: the duke experience.
Katsanis SH, Minear MA, Vorderstrasse A, Yang N, Reeves JW, Rakhra-Burris T, Cook-Deegan R, Ginsburg GS, Simmons LA. Katsanis SH, et al. J Pers Med. 2015 Apr 3;5(2):67-82. doi: 10.3390/jpm5020067. J Pers Med. 2015. PMID: 25854543 Free PMC article.
We assessed providers' use of genetic and genomic testing options and indications in clinical practice, providers' awareness of pharmacogenetic applications, and providers' opinions on returning research-generated genetic test results to participants. Most clinic
We assessed providers' use of genetic and genomic testing options and indications in clinical practice, providers' awareness o …
Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy.
Hertz DL. Hertz DL. Pharmacogenomics J. 2019 Oct;19(5):411-416. doi: 10.1038/s41397-019-0093-1. Epub 2019 Aug 9. Pharmacogenomics J. 2019. PMID: 31395959 Free PMC article. Review.
Clinician-rated toxicity data has been systematically collected within oncology clinical research using the National Cancer Institute's CTCAE scale, providing estimates of the occurrence and severity of toxicity from cancer treatment. CTCAE is being supplemen
Clinician-rated toxicity data has been systematically collected within oncology clinical research using the National Cancer In
Strategies for implementation of an effective pharmacogenomics program in pharmacy education.
Rao US, Mayhew SL, Rao PS. Rao US, et al. Pharmacogenomics. 2015 Jul;16(8):905-11. doi: 10.2217/pgs.15.50. Epub 2015 Jun 12. Pharmacogenomics. 2015. PMID: 26067487
However, this knowledge is not fully realized in clinical practice. One reason for this impasse is the lack of in-depth understanding of the potential of pharmacogenomics among the healthcare professionals. Pharmacists are the point-of-care providers and are …
However, this knowledge is not fully realized in clinical practice. One reason for this impasse is the lack of in-depth unders …
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?
Dias MM, Sorich MJ, Rowland A, Wiese MD, McKinnon RA. Dias MM, et al. Pharm Res. 2017 Aug;34(8):1544-1550. doi: 10.1007/s11095-017-2128-0. Epub 2017 Feb 24. Pharm Res. 2017. PMID: 28236061 Review.
However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and rei …
However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. …
Clinical Utilization of Pharmacogenetics in Psychiatry - Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry.
Brown L, Eum S, Haga SB, Strawn JR, Zierhut H. Brown L, et al. Pharmacopsychiatry. 2020 Jul;53(4):162-173. doi: 10.1055/a-0975-9595. Epub 2019 Sep 11. Pharmacopsychiatry. 2020. PMID: 31509860
INTRODUCTION: The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. ...METHODS: This is a narrative review of utilization of PGx testing in psychiatry from stakeholders including, pharmacists, genetic counse …
INTRODUCTION: The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. …
Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
Hess GP, Fonseca E, Scott R, Fagerness J. Hess GP, et al. Genet Res (Camb). 2015 Jun 1;97:e13. doi: 10.1017/S0016672315000099. Genet Res (Camb). 2015. PMID: 26030725 Free PMC article. Review.
However, PGx-guided therapy faces many barriers to full integration into clinical practice and acceptance by stakeholders, whether practitioner, patient or payer. ...The acceleration of adoption of precision medicine in general and for PGx testing in particular will …
However, PGx-guided therapy faces many barriers to full integration into clinical practice and acceptance by stakeholders, whe …
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback